The contrasting mechanisms of serum resistance of Neisseria gonorrhoeae and group B Neisseria meningitidis

Molecular Immunology

Volumn 36, Issue 13-14, 1999, Pages 915-928

  Ram, S ^a   Mackinnon, F G ^b   Gulati, S ^a   McQuillen, D P ^a   Vogel, U ^c   Frosch, M ^c   Elkins, C ^d   Guttormsen, H K ^e   Wetzler, L M ^a   Oppermann, M ^f   Pangburn, M K ^g   Rice, P A ^a  

^a BOSTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^g UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

C4b binding protein; Capsular polysaccharide; Complement; Factor H; Neisseria gonorrhoeae; Neisseria meningitidis; Porin

Indexed keywords

COMPLEMENT MEMBRANE ATTACK COMPLEX;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CELL KILLING; COMPLEMENT DEPENDENT CYTOTOXICITY; CONFERENCE PAPER; HOST RESISTANCE; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIALYLATION; STRAIN DIFFERENCE;

BLOOD BACTERICIDAL ACTIVITY; COMPLEMENT SYSTEM PROTEINS; HUMANS; LIPOPOLYSACCHARIDES; NEISSERIA GONORRHOEAE; NEISSERIA MENINGITIDIS; PORINS; SPECIES SPECIFICITY;

EID: 18344406352     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(99)00114-5     Document Type: Conference Paper

References (159)

1. Anon., 1997. Annual report of the Australian Meningococcal Surveillance Programme 1996. Commun. Dis. Intell. 21, 217-221.
2. Anon., 1998. Outbreaks of group B meningococcal disease - Florida, 1995 and 1997. MMWR Morb. Mortal Wkly Rep. 47, 833-837.
3. Alper C.A., Abramson N., Johnston R.B. Jr, Jandl J.H., Rosen F.S. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N. Engl. J. Med. 282:1970;350-354.
4. Apicella M.A., Mandrell R.E., Shero M., Wilson M.E., Griffiss J.M., Brooks G.F., Lammel C., Breen J.F., Rice P.A. Modification by sialic acid of Neisseria gonorrhoeae lipooligosaccharide epitope expression in human urethral exudates: an immunoelectron microscopic analysis. J. Infect. Dis. 162:1990;506-512.
5. Apicella M.A., Shero M., Jarvis G.A., Griffiss J.M., Mandrell R.E., Schneider H. Phenotypic variation in epitope expression of the Neisseria gonorrhoeae lipooligosaccharide. Infect. Immun. 55:1987;1755-1761.
6. Ashton F.E., Ryan A., Diena B., Jennings H.J. A new serogroup (L) of Neisseria meningitidis. J. Clin. Microbiol. 17:1983;722-727.
7. Barba G.M., Kaufmann T.J., Schneider P.M., Rittner C., Brai M. Polymorphism of the complement C8A and -B genes in two families with C8 beta deficiency and neisserial infections. Clin. Immunol. Immunopathol. 72:1994;83-89.
8. Barlow A.K., Heckels J.E., Clarke I.N. Molecular cloning and expression of Neisseria meningitidis class 1 outer membrane protein in Escherichia coli K-12. Infect. Immun. 55:1987;2734-2740.
9. Barlow A.K., Heckels J.E., Clarke I.N. The class 1 outer membrane protein of Neisseria meningitidis: gene sequence and structural and immunological similarities to gonococcal porins. Mol. Microbiol. 3:1989;131-139.
10. Berggard K., Johnsson E., Mooi F.R., Lindahl G. Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect. Immun. 65:1997;3638-3643.
11. Blackmore T.K., Hellwage J., Sadlon T.A., Higgs N., Zipfel P.F., Ward H.M., Gordon D.L. Identification of the second heparin-binding domain in human complement factor H. J. Immunol. 160:1998;3342-3348.
12. Blake M.S., Gotschlich E.C. Functional and immunological properties of pathogenic neisserial surface proteins. Inouye M. Bacterial Outer Membranes as Model Systems. 1986;377-400 John Wiley, New York.
13. Branham S. Serological relationship among meningococci. Bacteriol. Rev. 17:1953;175-188.
14. Branham S. Reference strains for the serologic groups of meningococcus (Neisseria meningitidis). Int. Bull. Bacteriol. Nomenclature Taxonomy. 8:1958;1-15.
15. Brunham R.C., Plummer F., Slaney L., Rand F., DeWitt W. Correlation of auxotype and protein I type with expression of disease due to Neisseria gonorrhoeae. J. Infect. Dis. 152:1985;339-343.
16. Butcher S., Sarvas M., Runeberg-Nyman K. Class-3 porin protein of Neisseria meningitidis: cloning and structure of the gene. Gene. 105:1991;125-128.
17. Cannon J.G., Buchanan T.M., Sparling P.F. Confirmation of association of protein I serotype of Neisseria gonorrhoeae with ability to cause disseminated infection. Infect. Immun. 40:1983;816-819.
18. Carbonetti N., Simnad V., Elkins C., Sparling P.F. Construction of isogenic gonococci with variable porin structure: effects on susceptibility to human serum and antibiotics. Mol. Microbiol. 4:1990;1009-1018.
19. Carbonetti N.H., Simnad V.I., Seifert H.S., So M., Sparling P.F. Genetics of protein I of Neisseria gonorrhoeae: construction of hybrid porins [published erratum appears in Proc. Natl. Acad. Sci. USA 1989 Feb;86(4):1317]. Proc. Natl. Acad. Sci. USA. 85:1988;6841-6845.
20. Caugant D.A., Froholm L.O., Bovre K., Holten E., Frasch C.E., Mocca L.F., Zollinger W.D., Selander R.K. Intercontinental spread of a genetically distinctive complex of clones of Neisseria meningitidis causing epidemic disease. Proc. Natl. Acad. Sci. USA. 83:1986;4927-4931.
21. China B., Sory M.P., N'Guyen B.T., De Bruyere M., Cornelis G.R. Role of the YadA protein in prevention of opsonization of Yersinia enterocolitica by C3b molecules. Infect. Immun. 61:1993;3129-3136.
22. Connolly M., Noah N. Is group C meningococcal disease increasing in Europe? A report of surveillance of meningococcal infection in Europe 1993-6 European Meningitis Surveillance Group. Epidemiol. Infect. 122:1999;41-49.
23. Crawford C., Knapp J.S., Hale J., Holmes K.K. Asymptomatic gonorrhea in men: caused by gonococci with unique nutritional requirements. Science. 196:1977;1352-1353.
24. Daha M.R., van Es L.A. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein. J. Immunol. 125:1980;2051-2054.
25. Densen P., Weiler J.M., Griffiss J.M., Hoffmann L.G. Familial properdin deficiency and fatal meningococcemia: Correction of the bactericidal defect by vaccination. N. Engl. J. Med. 316:1987;922-926.
26. Derrick J.P., Urwin R., Suker J., Feavers I.M., Maiden M.C. Structural and evolutionary inference from molecular variation in Neisseria porins. Infect. Immun. 67:1999;2406-2413.
27. DeVoe I.W. The meningococcus and mechanisms of pathogenicity. Microbiol. Rev. 46:1982;162-190.
28. Diermayer M., Hedberg K., Hoesly F., Fischer M., Perkins B., Reeves M., Fleming D. Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain [see comments]. JAMA. 281:1999;1493-1497.
29. Ding S.Q., Ye R.B., Zhang H.C. Three new serogroups of Neisseria meningitidis. J. Biol. Stand. 9:1981;307-315.
30. Douglas J.T., Lee M.D., Nikaido H. Protein I of Neisseria gonorrhoeae outer membrane is a porin. FEMS Microbiol. Lett. 12:1981;305-309.
31. Durand M.L., Calderwood S.B., Weber D.J., Miller S.I., Southwick F.S., Caviness V.S. Jr, Swartz M.N. Acute bacterial meningitis in adults: A review of 493 episodes [see comments]. N. Engl. J. Med. 328:1993;21-28.
32. Edwards M.S., Kasper D.L., Jennings H.J., Baker C.J., Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J. Immunol. 128:1982;1278-1283.
33. Ellison R.T.D., Kohler P.F., Curd J.G., Judson F.N., Reller L.B. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningocococcal disease. N. Engl. J. Med. 308:1983;913-916.
34. Estabrook M.M., Griffiss J.M., Jarvis G.A. Sialylation of Neisseria meningitidis lipooligosaccharide inhibits serum bactericidal activity by masking lacto-N-neotetraose. Infect. Immun. 65:1997;4436-4444.
35. Evans J.R., Artenstein M.S., Hunter D.H. Prevalence of meningococcal serogroups and description of three new groups. Am. J. Epidemiol. 87:1968;643-646.
36. Fearon D.T. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA. 75:1978;1971-1975.
37. Fearon D.T., Austen K.F. Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc. Natl. Acad. Sci. USA. 74:1977;1683-1687.
38. Figueroa J., Andreoni J., Densen P. Complement deficiency states and meningococcal disease. Immunol. Res. 12:1993;295-311.
39. Fijen C.A., Kuijper E.J., Hannema A.J., Sjoholm A.G., van Putten J.P. Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups [see comments]. Lancet. 2:1989;585-588.
40. Fischetti V.A., Horstmann R.D., Pancholi V. Location of the complement factor H binding site on streptococcal M6 protein. Infect. Immun. 63:1995;149-153.
41. Fox A.J., Curry A., Jones D.M., Demarco de Hormaeche R., Parsons N.J., Cole J.A., Smith H. The surface structure seen on gonococci after treatment with CMP-NANA is due to sialylation of surface lipopolysaccharide previously described as a 'capsule'. Microb. Pathog. 11:1991;199-210.
42. Fox A.J., Jones D.M., Gray S.J., Caugant D.A., Saunders N.A. An epidemiologically valuable typing method for Neisseria meningitidis by analysis of restriction fragment length polymorphisms. J. Med. Microbiol. 34:1991;265-270.
43. Fox A.J., Jones D.M., Scotland S.M., Rowe B., Smith A., Brown M.R., Fitzgeorge R.G., Baskerville A., Parsons N.J., Cole J.A., et al. Serum killing of meningococci and several other gram-negative bacterial species is not decreased by incubating them with cytidine 5'- monophospho-N-acetyl neuraminic acid [letter]. Microb. Pathog. 7:1989;317-318.
44. Frasch C., Gotschlich E. Noncapsular surface antigens of Neisseria meningitidis. Weinstein L., Fields B. Seminars in Infectious Diseases. 1979;304-337 Stratton International Medical Book Corporation, New York.
45. Frasch C., Zollinger W., Poolman J. Proposed schema for identification of serotypes of Neisseria meningitidis. Schoolnik G. The Pathogenic Neisseria. 1985;519-524 American Society for Microbiology, Washington, DC.
46. Frosch M., Weisgerber C., Meyer T.F. Molecular characterization and expression in Escherichia coli of the gene complex encoding the polysaccharide capsule of Neisseria meningitidis group B. Proc. Natl. Acad. Sci. USA. 86:1989;1669-1673.
47. Fujita T., Gigli I., Nussenzweig V. Human C4-binding protein. II. Role in proteolysis of C4b by C3b- inactivator. J. Exp. Med. 148:1978;1044-1051.
48. Fujita T., Nussenzweig V. The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J. Exp. Med. 150:1979;267-276.
49. Fujita T., Tamura N. Interaction of C4-binding protein with cell-bound C4b. A quantitative analysis of binding and the role of C4-binding protein in proteolysis of cell-bound C4b. J. Exp. Med. 157:1983;1239-1251.
50. Gigli I., Fujita T., Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc. Natl. Acad. Sci. USA. 76:1979;6596-6600.
51. Gilbert M., Watson D.C., Cunningham A.M., Jennings M.P., Young N.M., Wakarchuk W.W. Cloning of the lipooligosaccharide alpha-2,3-sialyltransferase from the bacterial pathogens Neisseria meningitidis and Neisseria gonorrhoeae. J. Biol. Chem. 271:1996;28271-28276.
52. Girgis N.I., Sippel J.E., Kilpatrick M.E., Sanborn W.R., Mikhail I.A., Cross E., Erian M.W., Sultan Y., Farid Z. Meningitis and encephalitis at the Abbassia Fever Hospital, Cairo, Egypt, from 1966 to 1989. Am. J. Trop. Med. Hyg. 48:1993;97-107.
53. Goldner M., Penn C.W., Sanyal S.C., Veale D.R., Smith H. Phenotypically determined resistance of Neisseria gonorrhoeae to normal human serum: environmental factors in subcutaneous chambers in guinea pigs. J. Gen. Microbiol. 114:1979;169-177.
54. Griffiss J.M., O'Brien J.P., Yamasaki R., Williams G.D., Rice P.A., Schneider H. Physical heterogeneity of Neisserial lipooligosaccharides reflects oligosaccharides that differ in apparent molecular weight, chemical composition, and antigenic expression. Infect. Immun. 55:1987;1792-1800.
55. Griffiss J.M., Schneider H., Mandrell R.E., Yamasaki R., Jarvis G.A., Kim J.J., Gibson B.W., Hamadeh R., Apicella M.A. Lipooligosaccharides: the principal glycolipids of the neisserial outer membrane. Rev. Infect. Dis. 10:(Suppl 2):1988;S287-S295.
56. Gulati S., McQuillen D.P., Mandrell R.E., Jani D.B., Rice P.A. Immunogenicity of Neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids [published erratum appears in J. Infect. Dis. 1997 Apr;175(4):1027]. J. Infect. Dis. 174:1996;1223-1237.
57. Gulati S., Ram S., McQuillen D.P., Pangburn M.K., Rice P.A. Factor H interactions with sialylated gonococcal lipooligosaccharide. Mol. Immunol. 35:1998;398. (abstract).
58. Hamadeh R.M., Estabrook M.M., Zhou P., Jarvis G.A., Griffiss J.M. Anti-Gal binds to pili of Neisseria meningitidis: the immunoglobulin A isotype blocks complement-mediated killing. Infect. Immun. 63:1995;4900-4906.
59. Hammerschmidt S., Birkholz C., Zahringer U., Robertson B.D., van Putten J., Ebeling O., Frosch M. Contribution of genes from the capsule gene complex (cps) to lipooligosaccharide biosynthesis and serum resistance in Neisseria meningitidis. Mol. Microbiol. 11:1994;885-896.
60. Hart C.A., Cuevas L.E. Meningococcal disease in Africa. Ann. Trop. Med. Parasitol. 91:1997;777-785.
61. Hirsch R.L., Griffin D.E., Winkelstein J.A. Host modification of Sindbis virus sialic acid content influences alternative complement pathway activation and virus clearance. J. Immunol. 127:1981;1740-1743.
62. Hirsch R.L., Griffin D.E., Winkelstein J.A. Natural immunity to Sindbis virus is influenced by host tissue sialic acid content. Proc. Natl. Acad. Sci. USA. 80:1983;548-550.
63. Hook J.E.W., Handsfield H.H. Gonococcal infections in the adult. Holmes K.K., Sparling P.F., Mardh P.A., Wiesner P.J., Cates J.W., Lemon S.M., Stamm W.E. Sexually Transmitted Diseases. 1999;451-466 McGraw-Hill, New York.
64. Horstmann R.D., Sievertsen H.J., Knobloch J., Fischetti V.A. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc. Natl. Acad. Sci. USA. 85:1988;1657-1661.
65. Ingwer I., Petersen B.H., Brooks G. Serum bactericidal action and activation of the classic and alternate complement pathways by Neisseria gonorrhoeae. J. Lab. Clin. Med. 92:1978;211-220.
66. Irwin D.J., Miller J.M., Milner P.C., Patterson T., Richards R.G., Williams D.A., Insley C.A., Stuart J.M. Community immunization programme in response to an outbreak of invasive Neisseria meningitidis serogroup C infection in the Trent region of England 1995-1996 [see comments]. J. Public Health Med. 19:1997;162-170.
67. Jack D.L., Dodds A.W., Anwar N., Ison C.A., Law A., Frosch M., Turner M.W., Klein N.J. Activation of complement by mannose-binding lectin on isogenic mutants of Neisseria meningitidis serogroup. Br. J. Immunol. 160:1998;1346-1353.
68. Jarvis G.A. Analysis of C3 deposition and degradation on Neisseria meningitidis and Neisseria gonorrhoeae. Infect. Immun. 62:1994;1755-1760.
69. Jarvis G.A. Recognition and control of neisserial infection by antibody and complement. Trends Microbiol. 3:1995;198-201.
70. Jarvis G.A., Griffiss J.M. Human IgA1 initiates complement-mediated killing of Neisseria meningitidis. J. Immunol. 143:1989;1703-1709.
71. Jarvis G.A., Vedros N.A. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect. Immun. 55:1987;174-180.
72. Jeanteur D., Lakey J.H., Pattus F. The bacterial porin superfamily: sequence alignment and structure prediction. Mol. Microbiol. 5:1991;2153-2164.
73. Johnsson E., Thern A., Dahlback B., Heden L.O., Wikstrom M., Lindahl G. A highly variable region in members of the streptococcal M protein family binds the human complement regulator C4BP. J. Immunol. 157:1996;3021-3029.
74. Joiner K.A., Hammer C.H., Brown E.J., Cole R.J., Frank M.M. Studies on the mechanism of bacterial resistance to complement-mediated killing. I. Terminal complement components are deposited and released from Salmonella minnesota S218 without causing bacterial death. J. Exp. Med. 155:1982;797-808.
75. Joiner K.A., Hammer C.H., Brown E.J., Frank M.M. Studies on the mechanism of bacterial resistance to complement-mediated killing. II. C8 and C9 release C5b67 from the surface of Salmonella minnesota S218 because the terminal complex does not insert into the bacterial outer membrane. J. Exp. Med. 155:1982;809-819.
76. Jokiranta T.S., Hellwage J., Koistinen V., Zipfel P.F., Meri S. Each of the three binding sites on factor H interacts with a distinct site on C3b. Mol. Immunol. 35:1998;360. (abstract).
77. Jokiranta T.S., Zipfel P.F., Hakulinen J., Kuhn S., Pangburn M.K., Tamerius J.D., Meri S. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett. 393:1996;297-302.
78. Jones D.M., Borrow R., Fox A.J., Gray S., Cartwright K.A., Poolman J.T. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb. Pathog. 13:1992;219-224.
79. Kahler C.M., Martin L.E., Shih G.C., Rahman M.M., Carlson R.W., Stephens D.S. The (α2→8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect. Immun. 66:1998;5939-5947.
80. Kazatchkine M.D., Fearon D.T., Austen K.F. Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and β1H for cell-bound C3b. J. Immunol. 122:1979;75-81.
81. Kertesz D.A., Coulthart M.B., Ryan J.A., Johnson W.M., Ashton F.E. Serogroup B, electrophoretic type 15 Neisseria meningitidis in Canada. J. Infect. Dis. 177:1998;1754-1757.
82. Kihlberg B.M., Collin M., Olsen A., Bjorck L. Protein H, an antiphagocytic surface protein in Streptococcus pyogenes. Infect. Immun. 67:1999;1708-1714.
83. Knapp J.S., Sandstrom E.G., Holmes K.K. Overview of epidemiological and clinical applications of auxotype/serovar classification of Neisseria gonorrhoeae. Schoolnik G.K. The Pathogenic Neisseriae. 1985;6-12 American Society for Microbiology, Washington, DC.
84. Knapp J.S., Tam M.R., Nowinski R.C., Holmes K.K., Sandstrom E.G. Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I. J. Infect. Dis. 150:1984;44-48.
85. Lehner P.J., Davies K.A., Walport M.J., Cope A.P., Wurzner R., Orren A., Morgan B.P., Cohen J. Meningococcal septicaemia in a C6-deficient patient and effects of plasma transfusion on lipopolysaccharide release. Lancet. 340:1992;1379-1381.
86. Lepow M.L., Beeler J., Randolph M., Samuelson J.S., Hankins W.A. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children. J. Infect. Dis. 154:1986;1033-1036.
87. Lim D., Gewurz A., Lint T.F., Ghaze M., Sepheri B., Gewurz H. Absence of the sixth component of complement in a patient with repeated episodes of meningococcal meningitis. J. Pediatr. 89:1976;42-47.
88. Liszewski M.K., Leung M.K., Atkinson J.P. Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. J. Immunol. 161:1998;3711-3718.
89. Luo N., Perera C., Holton J., Ayles H., Zumla A. Spread of Neisseria meningitidis group A clone III-I meningitis epidemic into Zambia. J. Infect. 36:1998;141-143.
90. Mackinnon F.G., Borrow R., Gorringe A.R., Fox A.J., Jones D.M., Robinson A. Demonstration of lipooligosaccharide immunotype and capsule as virulence factors for Neisseria meningitidis using an infant mouse intranasal infection model. Microb. Pathog. 15:1993;359-366.
91. Mackinnon F.G., Gulati S., Gorringe A., Oppermann M., Rice P.A., Ram S. The molecular basis of serum resistance in group B meningococci: inhibition of membrane attack complex insertion by capsular polysaccharide. Mol. Immunol. 36:1999;295. (abstract).
92. Mandrell R.E., Kim J.J., John C.M., Gibson B.W., Sugai J.V., Apicella M.A., Griffiss J.M., Yamasaki R. Endogenous sialylation of the lipooligosaccharides of Neisseria meningitidis. J. Bacteriol. 173:1991;2823-2832.
93. Mandrell R.E., Lesse A.J., Sugai J.V., Shero M., Griffiss J.M., Cole J.A., Parsons N.J., Smith H., Morse S.A., Apicella M.A. In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation. J. Exp. Med. 171:1990;1649-1664.
94. Martin P.M., Patel P.V., Parsons N.J., Smith H. Induction of phenotypically determined resistance of Neisseria gonorrhoeae to human serum by factors in human serum. J. Gen. Microbiol. 127:1981;213-217.
95. Masson L., Holbein B.E. Influence of nutrient limitation and low pH on serogroup B Neisseria meningitidis capsular polysaccharide levels: correlation with virulence for mice. Infect. Immun. 47:1985;465-471.
96. Masson L., Holbein B.E., Ashton F.E. Virulence linked to polysaccharide production in serogroup B Neisseria meningitidis. FEMS Microbiol. Lett. 13:1982;187-190.
97. McQuillen D.P., Gulati S., Ram S., Turner A.K., Jani D.B., Heeren T.C., Rice P.A. Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. J. Infect. Dis. 179:1999;124-135.
98. Meri S., Pangburn M.K. Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem. Biophys. Res. Commun. 198:1994;52-59.
99. Moran E.E., Brandt B.L., Zollinger W.D. Expression of the L8 lipopolysaccharide determinant increases the sensitivity of Neisseria meningitidis to serum bactericidal activity. Infect. Immun. 62:1994;5290-5295.
100. Morris J.T., Kelly W.J. Recurrence of neisserial meningococcemia due to deficiency of terminal complement component. South. Med. J. 85:1992;1030-1031.
101. Nairn C.A., Cole J.A., Patel P.V., Parsons N.J., Fox J.E., Smith H. Cytidine 5′-monophospho-N-acetylneuraminic acid or a related compound is the low Mr factor from human red blood cells which induces gonococcal resistance to killing by human serum. J. Gen. Microbiol. 134:1988;3295-3306.
102. Nejmi S., Belhaj A., Guibourdenche M., Riou J.Y. [Study of ninety strains of serogroup A Neisseria meningitidis isolated from cerebrospinal fluid (25) and rhinopharynx (65) in Morocco (December 1989-April 1990)]. Pathol. Biol. (Paris). 40:1992;993-998.
103. Nielsen H.E., Koch C., Magnussen P., Lind I. Complement deficiencies in selected groups of patients with meningococcal disease. Scand. J. Infect. Dis. 21:1989;389-396.
104. O'Brien J.P., Goldenberg D.L., Rice P.A. Disseminated gonococcal infection: a prospective analysis of 49 patients and a review of pathophysiology and immune mechanisms. Medicine. 62:1983;395-406.
105. Ollert M.W., David K., Bredehorst R., Vogel C.W. Classical complement pathway activation on nucleated cells. Role of factor H in the control of deposited C3b. J. Immunol. 155:1995;4955-4962.
106. Oppermann M., Schulze M., Gotze O. A sensitive enzyme immunoassay for the quantitation of human C5a/C5a(desArganaphylatoxin using a monoclonal antibody with specificity for a neoepitope. Complement Inflamm. 8:1991;13-24.
107. Orren A., Caugant D.A., Fijen C.A., Dankert J., van Schalkwyk E.J., Poolman J.T., Coetzee G.J. Characterization of strains of Neisseria meningitidis recovered from complement-sufficient and complement-deficient patients in the Western Cape Province, South Africa. J. Clin. Microbiol. 32:1994;2185-2191.
108. Pangburn M.K., Schreiber R.D., Muller-Eberhard H.J. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J. Exp. Med. 146:1977;257-270.
109. Parsons N.J., Curry A., Fox A.J., Jones D.M., Cole J.A., Smith H. The serum resistance of gonococci in the majority of urethral exudates is due to sialylated lipopolysaccharide seen as a surface coat. FEMS Microbiol. Lett. 69:1992;295-299.
110. Parsons N.J., Patel P.V., Tan E.L., Andrade J.R., Nairn C.A., Goldner M., Cole J.A., Smith H. Cytidine 5′-monophospho-N-acetyl neuraminic acid and a low molecular weight factor from human blood cells induce lipopolysaccharide alteration in gonococci when conferring resistance to killing by human serum. Microb. Pathog. 5:1988;303-309.
111. Patel M.S., Merianos A., Hanna J.N., Vartto K., Tait P., Morey F., Jayathissa S. Epidemic meningococcal meningitis in central Australia, 1987-1991 [see comments]. Med. J. Aust. 158:1993;336-340.
112. Patel P.V., Martin P.M., Goldner M., Parsons N.J., Smith H. Red blood cells, a source of factors which induce Neisseria gonorrhoeae to resistance to complement-mediated killing by human serum. J. Gen. Microbiol. 130:1984;2767-2770.
113. Patel P.V., Veale D.R., Fox J.E., Martin P.M., Parsons N.J., Smith H. Fractionation of guinea pig serum for an inducer of gonococcal resistance to killing by human serum: active fractions containing glucopeptides similar to those from human red blood cells. J. Gen. Microbiol. 130:1984;2757-2766.
114. Patel P.V., Martin P.M., Tan E.L., Nairn C.A., Parsons N.J., Goldner M., Smith H. Protein changes associated with induced resistance of Neisseria gonorrhoeae to killing by human serum are relatively minor. J. Gen. Microbiol. 134:1988;499-507.
115. Petersen B.H., Graham J.A., Brooks G.F. Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity. J. Clin. Invest. 57:1976;283-290.
116. Pinter C., Siccardi A.G., Longhi R., Clivio A. Direct interaction of complement factor H with the C1 domain of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses. 11:1995;577-588.
117. Pinter C., Siccardi A.G., Lopalco L., Longhi R., Clivio A. HIV glycoprotein 41 and complement factor H interact with each other and share functional as well as antigenic homology. AIDS Res. Hum. Retroviruses. 11:1995;971-980.
118. Prodinger W.M., Hellwage J., Spruth M., Dierich M.P., Zipfel P.F. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem. J. 331:1998;41-47.
119. Ram S., McQuillen D.P., Boden R., Gulati S., Pangburn M.K., Rice P.A. Neisseria gonorrhoeae regulate the classical pathway by directly binding C4-binding protein. Mol. Immunol. 35:1998;398. (abstract).
120. Ram S., McQuillen D.P., Gulati S., Elkins C., Pangburn M.K., Rice P.A. Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of non-sialylated Neisseria gonorrhoeae. J. Exp. Med. 188:1998;671-680.
121. Ram S., Sharma A.K., Simpson S.D., Gulati S., McQuillen D.P., Pangburn M.K., Rice P.A. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187:1998;743-752.
122. Ram S., Gulati S., McQuillen D.P., Boden R., Elkins C., Pangburn M.K., Rice P.A. Interactions between Neisseria gonorrhoeae and C4b-binding protein: a molecular basis for gonococcal serum resistance. Mol. Immunol. 36:1999;297. (abstract).
123. Ram S., Vogel U., Gulati S., Heinze G., Wetzler L., Guttormsen H.-K., Frosch M., Rice P.A. The interaction between factor H and Neisseria meningitidis. Mol. Immunol. 36:1999;297. (abstract).
124. Rice P.A. Molecular basis for serum resistance in Neisseria gonorrhoeae. Clin. Microbiol. Rev. 2S:1989;S112-S117.
125. Rice P.A., Goldenberg D.L. Clinical manifestations of disseminated infection caused by Neisseria gonorrhoeae are linked to differences in bactericidal reactivity of infecting strains. Ann. Intern. Med. 95:1981;175-178.
126. Riordan T. A college outbreak of group C meningococcal infection: how widely should investigation and prophylaxis extend? Commun. Dis. Rep. CDR Rev. 7:1997;R5-R9.
127. Ripoche J., Day A.J., Harris T.J., Sim R.B. The complete amino acid sequence of human complement factor H. Biochem. J. 249:1988;593-602.
128. Rosen M.S., Lorber B., Myers A.R. Chronic meningococcal meningitis. An association with C5 deficiency. Arch. Intern. Med. 148:1988;1441-1442.
129. Sadlon T.A., Parker S.J., Gordon D.L. Regulation of C3 deposition on gp120 coated CD4 positive cells by decay accelerating factor and factor H. Immunol. Cell Biol. 72:1994;461-470.
130. Sandstrom E.G., Chen K.C., Buchanan T.M. Serology of Neisseria gonorrhoeae: coagglutination serogroups WI and WII/III correspond to different outer membrane protein I molecules. Infect. Immun. 38:1982;462-470.
131. Scharfstein J., Ferreira A, Gigli I., Nussenzweig V. Human C4-binding protein. I. Isolation and characterization. J. Exp. Med. 148:1978;207-222.
132. Schneider H., Hammack C.A., Apicella M.A., Griffiss J.M. Instability of expression of lipooligosaccharides and their epitopes in Neisseria gonorrhoeae. Infect. Immun. 56:1988;942-946.
133. Scholten R.J., Bijlmer H.A., Poolman J.T., Kuipers B., Caugant D.A., Van Alphen L., Dankert J., Valkenburg H.A. Meningococcal disease in The Netherlands 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis. Clin. Infect. Dis. 16:1993;237-246.
134. Sharma A.K., Pangburn M.K. Biologically active recombinant human complement factor H: synthesis and secretion by the baculovirus system. Gene. 143:1994;301-302.
135. Sharma A.K., Pangburn M.K. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc. Natl. Acad. Sci. USA. 93:1996;10996-11001.
136. Sim E., Wood A.B., Hsiung L.M., Sim R.B. Pattern of degradation of human complement fragment, C3b. FEBS Lett. 132:1981;55-60.
137. Slaterus K. Serological typing of meningococci by means of microprecipitation. Antonie Van Leeuwenhoek. 27:1961;304-315.
138. Smith N.H., Maynard Smith J., Spratt B.G. Sequence evolution of the porB gene of Neisseria gonorrhoeae and Neisseria meningitidis: evidence of positive Darwinian selection. Mol. Biol. Evol. 12:1995;363-370.
139. Soderstrom C., Sjoholm A.G., Svensson R., Ostenson S. Another Swedish family with complete properdin deficiency: association with fulminant meningococcal disease in one male family member. Scand. J. Infect. Dis. 21:1989;259-265.
140. Soper D.E. Pelvic inflammatory disease. Infect. Dis. Clin. North. Am. 8:1994;821-840.
141. Sparling P.F. Biology of Neisseria gonorrhoeae. Holmes K.K., Mardh P.A., Sparling P.F., Wiesner P.J., Cates J.W., Lemon S.M., Stamm W.E. Sexually Transmitted Diseases. 1990;McGraw-Hill, New York.
142. Stoiber H., Ebenbichler C., Schneider R., Janatova J., Dierich M.P. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1. Aids. 9:1995;19-26.
143. Stoiber H., Schneider R., Janatova J., Dierich M.P. Human complement proteins C3b, C4b, factor H and properdin react with specific sites in gp120 and gp41, the envelope proteins of HIV-1. Immunobiology. 193:1995;98-113.
144. Tan E.L., Patel P.V., Parsons N.J., Martin P.M., Smith H. Lipopolysaccharide alteration is associated with induced resistance of Neisseria gonorrhoeae to killing by human serum. J. Gen. Microbiol. 132:1986;1407-1413.
145. Tomlinson S., Pontes de Carvalho L.C., Vandekerckhove F., Nussenzweig V. Role of sialic acid in the resistance of Trypanosoma cruzi trypomastigotes to complement. J. Immunol. 153:1994;3141-3147.
146. Tsai C.M., Civin C.I. Eight lipooligosaccharides of Neisseria meningitidis react with a monoclonal antibody which binds lacto-N-neotetraose (Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc). Infect. Immun. 59:1991;3604-3609.
147. Veale D.R., Penn C.W., Smith H. Factors affecting the induction of phenotypically determined serum resistance of Neisseria gonorrhoeae grown in media containing serum or its diffusible components. J. Gen. Microbiol. 122:1981;235-245.
148. Vogel U., Claus H., Heinze G., Frosch M. Functional characterization of an isogenic meningococcal alpha-2,3- sialyltransferase mutant: the role of lipooligosaccharide sialylation for serum resistance in serogroup B meningococci. Med. Microbiol. Immunol. (Berl.). 186:1997;159-166.
149. Vogel U., Weinberger A., Frank R.A.M., Kohl J., Atkinson J.P., Frosch M. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect. Immun. 65:1997;4022-4029.
150. Vogel U., Weinberger A., Frank R., Muller A., Kohl J., Atkinson J.P., Frosch M. Complement factor C3 deposition and serum resistance in isogenic capsule and lipooligosaccharide sialic acid mutants of serogroup B Neisseria meningitidis. Infect. Immun. 65:1997;4022-4029.
151. Vogel U., Claus H., Heinze G., Frosch M. Role of lipopolysaccharide sialylation in serum resistance of serogroup B and C meningococcal disease isolates. Infect. Immun. 67:1999;954-957.
152. Vogel U., Hammerschmidt S., Frosch M. Sialic acids of both the capsule and the sialylated lipooligosaccharide of Neisseria meningitis serogroup B are prerequisites for virulence of meningococci in the infant rat. Med. Microbiol. Immunol. (Berl.). 185:1996;81-87.
153. Ward M.E., Watt P.J., Glynn A.A. Gonococci in urethral exudates possess a virulence factor lost on subculture. Nature. 227:1970;382-384.
154. Ward M.J., Lambden P.R., Heckels J.E. Sequence analysis and relationships between meningococcal class 3 serotype proteins and other porins from pathogenic and non-pathogenic Neisseria species. FEMS Microbiol Lett. 73:1992;283-289.
155. Weiler J.M., Daha M.R., Austen K.F., Fearon D.T. Control of the amplification convertase of complement by the plasma protein beta1H. Proc. Natl. Acad. Sci. USA. 73:1976;3268-3272.
156. Whaley K., Ruddy S. Modulation of the alternative complement pathways by beta 1 H globulin. J. Exp. Med. 144:1976;1147-1163.
157. Zaleski A., Densen P. Sialylation of LOS inhibits gonococcal killing primarily through an effect on classical pathway activation. Zollinger W.D., Frasch C.E., Deal C.D. Abstracts of the Tenth International Pathogenic Neisseria Conference. 1996;114 National Institutes of Health, Baltimore, MD.
158. Zipfel P.F., Hellwage J., Friese M.A., Hegasy G., Jokiranta S.T., Meri S. Factor H and disease: a complement regulator affects vital body functions [In Process Citation]. Mol. Immunol. 36:1999;241-248.
159. Zollinger W.D., Mandrell R.E. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:1983;257-264.